These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

136 related items for PubMed ID: 29442417

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. Sustained elevated intraocular pressures after intravitreal injection of bevacizumab, ranibizumab, and pegaptanib.
    Choi DY, Ortube MC, McCannel CA, Sarraf D, Hubschman JP, McCannel TA, Gorin MB.
    Retina; 2011 Jun; 31(6):1028-35. PubMed ID: 21836409
    [Abstract] [Full Text] [Related]

  • 4. Intraocular pressure changes related to intravitreal injections of ranibizumab: analysis of pseudophakia and glaucoma subgroup.
    Demirel S, Yanik O, Batioglu F, Ozmert E.
    Int Ophthalmol; 2015 Aug; 35(4):541-7. PubMed ID: 25079762
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Ocular Hypertension Following Intravitreal Antivascular Endothelial Growth Factor Therapy: Review of the Literature and Possible Role of Nitric Oxide.
    Morshedi RG, Ricca AM, Wirostko BM.
    J Glaucoma; 2016 Mar; 25(3):291-300. PubMed ID: 25318578
    [Abstract] [Full Text] [Related]

  • 10. Long-Term Effect of Anti-VEGF Agents on Intraocular Pressure in Age-Related Macular Degeneration.
    Beato J, Pedrosa AC, Pinheiro-Costa J, Freitas-da-Costa P, Falcão MS, Melo A, Estrela-Silva S, Falcão-Reis F, Carneiro ÂM.
    Ophthalmic Res; 2016 Mar; 56(1):30-4. PubMed ID: 27046391
    [Abstract] [Full Text] [Related]

  • 11. Intraocular pressure in patients with neovascular age-related macular degeneration switched to aflibercept injection after previous anti-vascular endothelial growth factor treatments.
    Rusu IM, Deobhakta A, Yoon D, Lee M, Slakter JS, Klancnik JM, Thompson D, Freund KB.
    Retina; 2014 Nov; 34(11):2161-6. PubMed ID: 25072648
    [Abstract] [Full Text] [Related]

  • 12. Intravitreal injection of bevacizumab: changes in intraocular pressure related to ocular axial length.
    Cacciamani A, Oddone F, Parravano M, Scarinci F, Di Nicola M, Lofoco G.
    Jpn J Ophthalmol; 2013 Jan; 57(1):63-7. PubMed ID: 23093311
    [Abstract] [Full Text] [Related]

  • 13. Clinical predictors of sustained intraocular pressure elevation due to intravitreal anti-vascular endothelial growth factor therapy.
    Hoang QV, Tsuang AJ, Gelman R, Mendonca LS, Della Torre KE, Jung JJ, Freund KB.
    Retina; 2013 Jan; 33(1):179-87. PubMed ID: 22990314
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Does intravitreal injections of bevacizumab for age-related macular degeneration affect long-term intraocular pressure?
    Kim D, Nam WH, Kim HK, Yi K.
    J Glaucoma; 2014 Sep; 23(7):446-8. PubMed ID: 23632401
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Major factors affecting intraocular pressure spike after intravitreal ranibizumab injection: Vitreous reflux and its amount.
    Uyar E, Ulas F, Sahin S, Celebi S.
    Eur J Ophthalmol; 2019 Jul; 29(4):361-367. PubMed ID: 30947538
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Intraocular pressure effects of pegaptanib (macugen) injections in patients with and without glaucoma.
    Lanzl IM, Maier M, Feucht N, Lohmann CP, Kotliar KE.
    Am J Ophthalmol; 2008 Jan; 145(1):185; author reply 186. PubMed ID: 18154762
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 7.